Recursion, one of the most buzzed-about startups using machine learning to speed up drug discovery trials, said Wednesday it raised $239 million in Series D led by pharmaceutical maker Bayer. Recursion’s pre-investment valuation was a hair below $1 billion, according to a person with knowledge of the matter. Separately, Bayer is paying the seven-year-old Salt Lake City-based company $30 million...
Get access to exclusive coverage
Read deeply reported stories from the largest newsroom in tech.
The AI Age e-commerce ai
How to Grease a Chatbot: E-Commerce Companies Seek a Backdoor Into AI Responses
When Andy Wilson’s company received its first successful client referral through ChatGPT, he was shaken to his core. The founder and CEO of Logikcull, a San Francisco–based legal technology company, Wilson “had the exact same reaction to ChatGPT as I had to the internet browser in the early ’90s,” he said. “But this time I knew it would be even bigger than...
Stay in the know
Receive a summary of the day's top tech news—distilled into one email.
Access on the go
View stories on our mobile app and tune into our weekly podcast.
Join live video Q&A’s
Deep-dive into topics like startups and autonomous vehicles with our top reporters and other executives.
Enjoy a clutter-free experience
Read without any banner ads.
Recent Popular Stories
How Microsoft Swallowed Its Pride to Make a Massive Bet on OpenAI
Satya Nadella didn’t want to hear it. Last December, Peter Lee, who oversees Microsoft’s sprawling research efforts, was briefing Nadella, Microsoft’s CEO, and his deputies about a series of tests Microsoft had conducted of GPT-4, the then-unreleased new artificial intelligence large-language model built by OpenAI.